Oncology Phase 3 Deal Benchmarks (2026)
Median upfront of $615M with total deal values reaching $3.4B.
Median Upfront
$615M
Total Deal Value
$2.7B
Royalty Range
10.1%–19.8%
Territory Multiplier
1x
Understanding Oncology Deal Benchmarks at Phase 3
Phase 3 Oncology licensing deals command a median upfront payment of $615M, with values ranging from $403M at the low end to $792M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $2.0B to $3.4B, with a median of $2.7B. Royalty rates for oncology assets at this stage typically fall between 10.1% and 19.8% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $403M | $615M | $792M |
| Total Deal Value | $2.0B | $2.7B | $3.4B |
| Royalty Rate | 10.1% | — | 19.8% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2023 | Daiichi Sankyo | Merck | $4.0B | $22.0B | codevelopment |
| 2023 | Daiichi Sankyo | AstraZeneca | $1.0B | $6.9B | codevelopment |
| 2024 | Iovance Biotherapeutics | Roche | $150M | $1.2B | collaboration |
| 2023 | Seagen | Pfizer | $43.0B | $43.0B | acquisition |
| 2024 | ImmunoGen | AbbVie | $10.1B | $10.1B | acquisition |
| 2024 | Eisai | Merck | $0M | $5.8B | collaboration |
| 2024 | AstraZeneca | Daiichi Sankyo | $2.0B | $6.0B | codevelopment |
| 2023 | BMS | N/A (standalone) | $0M | $4.0B | licensing |
| 2024 | Genmab | AbbVie | $750M | $3.5B | codevelopment |
| 2024 | Syndax Pharmaceuticals | Incyte | $200M | $1.4B | collaboration |
See All Comparable Deals
View 10 comparable Oncology transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 3 Oncology deals?
How does Global territory affect Oncology deal value?
What royalty rates are typical for Phase 3 Oncology licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$64M upfront
Oncology · Preclinical · Global
$128M upfront
Oncology · Phase 1 · Global
$235M upfront
Oncology · Phase 2 · Global
$947M upfront
Oncology · Approved · Global
$471M upfront
Neurology/CNS · Phase 3 · Global
$1.1B upfront
Immunology · Phase 3 · Global
$365M upfront
Metabolic/Obesity · Phase 3 · Global
$338M upfront
Oncology · Phase 3 · US Only
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Oncology Phase 3 Deal Benchmarks (2026). Retrieved from https://solidus.ambrosiaventures.co/data/oncology-phase-3-deals-global
<a href="https://solidus.ambrosiaventures.co/data/oncology-phase-3-deals-global">Oncology Phase 3 Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=oncology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.